Antibodies to the receptor-binding domain of the SARS-Cov-2 spike protein: association with age, pneumonia, duration of the period after COVID-19
Despite the rapid accumulation of facts about the humoral immune response in COVID-19, there are still no evidencebased answers to questions about the factors influencing the level and duration of the detection period of antibodies to SARS-CoV-2 in the blood.Objective: To assess the prevalence, clin...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Journal Infectology
2022-04-01
|
| Series: | Журнал инфектологии |
| Subjects: | |
| Online Access: | https://journal.niidi.ru/jofin/article/view/1310 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849398692464820224 |
|---|---|
| author | E. A. Kolosova O. N. Shaprova Yu. A. Nikulina D. V. Shanshin V. S. Nesmeyanova Yu. A. Merkuleva S. V. Belenkaya A. A. Isaeva D. N. Shcherbakov S. A. Elchaninova M. A. Nikonorova |
| author_facet | E. A. Kolosova O. N. Shaprova Yu. A. Nikulina D. V. Shanshin V. S. Nesmeyanova Yu. A. Merkuleva S. V. Belenkaya A. A. Isaeva D. N. Shcherbakov S. A. Elchaninova M. A. Nikonorova |
| author_sort | E. A. Kolosova |
| collection | DOAJ |
| description | Despite the rapid accumulation of facts about the humoral immune response in COVID-19, there are still no evidencebased answers to questions about the factors influencing the level and duration of the detection period of antibodies to SARS-CoV-2 in the blood.Objective: To assess the prevalence, clinical and demographic associations of IgG antibodies to RBD of the SARSCoV-2 spike protein at different times after COVID-19.Materials and methods. Residents of the Altai region of Russia, Caucasians aged 20-93 years, who had COVID-19 from May 2020 to February 2021 (n = 314), took part in a onetime observational study. The level of antibodies in the blood was measured by enzyme-linked immunosorbent assay 1-14 months after the onset of the clinical manifestation of COVID-19.Results. Anti-RBD IgG antibodies of the SARS-CoV-2 spike protein were detected in 86.9% of the study participants. The dependence of the antibody titer on the duration of the period after COVID-19 was not revealed. The antibody titer was positively correlated with the complication of COVID-19 pneumonia and the volume of lung tissue lesions. The presence of pneumonia COVID-19 and the volume of lung tissue lesions are positively associated with age. Age positively correlated with antibody titer regardless of the pneumonia COVID-19 in the anamnesis.Conclusion. IgG antibodies to RBD of the SARS-CoV-2 spike protein are present in most of the COVID-19 patients. The titer of these antibodies in adults depends on age, complications of pneumonia COVID-19, and probably persists up to 14 months after the first symptoms of infection appear. |
| format | Article |
| id | doaj-art-7a9a90c1cd754c7a9c6033539f2b7c86 |
| institution | Kabale University |
| issn | 2072-6732 |
| language | Russian |
| publishDate | 2022-04-01 |
| publisher | Journal Infectology |
| record_format | Article |
| series | Журнал инфектологии |
| spelling | doaj-art-7a9a90c1cd754c7a9c6033539f2b7c862025-08-20T03:38:31ZrusJournal InfectologyЖурнал инфектологии2072-67322022-04-01141697710.22625/2072-6732-2022-14-1-69-77971Antibodies to the receptor-binding domain of the SARS-Cov-2 spike protein: association with age, pneumonia, duration of the period after COVID-19E. A. Kolosova0O. N. Shaprova1Yu. A. Nikulina2D. V. Shanshin3V. S. Nesmeyanova4Yu. A. Merkuleva5S. V. Belenkaya6A. A. Isaeva7D. N. Shcherbakov8S. A. Elchaninova9M. A. Nikonorova10The State Scientific Center of Virology and Biotechnology «Vector»; Altai State UniversityThe State Scientific Center of Virology and Biotechnology «Vector»Altai State Medical UniversityThe State Scientific Center of Virology and Biotechnology «Vector»; Altai State UniversityThe State Scientific Center of Virology and Biotechnology «Vector»The State Scientific Center of Virology and Biotechnology «Vector»The State Scientific Center of Virology and Biotechnology «Vector»The State Scientific Center of Virology and Biotechnology «Vector»The State Scientific Center of Virology and Biotechnology «Vector»; Altai State UniversityAltai State Medical UniversityAltai State Medical UniversityDespite the rapid accumulation of facts about the humoral immune response in COVID-19, there are still no evidencebased answers to questions about the factors influencing the level and duration of the detection period of antibodies to SARS-CoV-2 in the blood.Objective: To assess the prevalence, clinical and demographic associations of IgG antibodies to RBD of the SARSCoV-2 spike protein at different times after COVID-19.Materials and methods. Residents of the Altai region of Russia, Caucasians aged 20-93 years, who had COVID-19 from May 2020 to February 2021 (n = 314), took part in a onetime observational study. The level of antibodies in the blood was measured by enzyme-linked immunosorbent assay 1-14 months after the onset of the clinical manifestation of COVID-19.Results. Anti-RBD IgG antibodies of the SARS-CoV-2 spike protein were detected in 86.9% of the study participants. The dependence of the antibody titer on the duration of the period after COVID-19 was not revealed. The antibody titer was positively correlated with the complication of COVID-19 pneumonia and the volume of lung tissue lesions. The presence of pneumonia COVID-19 and the volume of lung tissue lesions are positively associated with age. Age positively correlated with antibody titer regardless of the pneumonia COVID-19 in the anamnesis.Conclusion. IgG antibodies to RBD of the SARS-CoV-2 spike protein are present in most of the COVID-19 patients. The titer of these antibodies in adults depends on age, complications of pneumonia COVID-19, and probably persists up to 14 months after the first symptoms of infection appear.https://journal.niidi.ru/jofin/article/view/1310covid-19antibodiesreceptor-binding domains-proteinsars-cov-2agepneumonia |
| spellingShingle | E. A. Kolosova O. N. Shaprova Yu. A. Nikulina D. V. Shanshin V. S. Nesmeyanova Yu. A. Merkuleva S. V. Belenkaya A. A. Isaeva D. N. Shcherbakov S. A. Elchaninova M. A. Nikonorova Antibodies to the receptor-binding domain of the SARS-Cov-2 spike protein: association with age, pneumonia, duration of the period after COVID-19 Журнал инфектологии covid-19 antibodies receptor-binding domain s-protein sars-cov-2 age pneumonia |
| title | Antibodies to the receptor-binding domain of the SARS-Cov-2 spike protein: association with age, pneumonia, duration of the period after COVID-19 |
| title_full | Antibodies to the receptor-binding domain of the SARS-Cov-2 spike protein: association with age, pneumonia, duration of the period after COVID-19 |
| title_fullStr | Antibodies to the receptor-binding domain of the SARS-Cov-2 spike protein: association with age, pneumonia, duration of the period after COVID-19 |
| title_full_unstemmed | Antibodies to the receptor-binding domain of the SARS-Cov-2 spike protein: association with age, pneumonia, duration of the period after COVID-19 |
| title_short | Antibodies to the receptor-binding domain of the SARS-Cov-2 spike protein: association with age, pneumonia, duration of the period after COVID-19 |
| title_sort | antibodies to the receptor binding domain of the sars cov 2 spike protein association with age pneumonia duration of the period after covid 19 |
| topic | covid-19 antibodies receptor-binding domain s-protein sars-cov-2 age pneumonia |
| url | https://journal.niidi.ru/jofin/article/view/1310 |
| work_keys_str_mv | AT eakolosova antibodiestothereceptorbindingdomainofthesarscov2spikeproteinassociationwithagepneumoniadurationoftheperiodaftercovid19 AT onshaprova antibodiestothereceptorbindingdomainofthesarscov2spikeproteinassociationwithagepneumoniadurationoftheperiodaftercovid19 AT yuanikulina antibodiestothereceptorbindingdomainofthesarscov2spikeproteinassociationwithagepneumoniadurationoftheperiodaftercovid19 AT dvshanshin antibodiestothereceptorbindingdomainofthesarscov2spikeproteinassociationwithagepneumoniadurationoftheperiodaftercovid19 AT vsnesmeyanova antibodiestothereceptorbindingdomainofthesarscov2spikeproteinassociationwithagepneumoniadurationoftheperiodaftercovid19 AT yuamerkuleva antibodiestothereceptorbindingdomainofthesarscov2spikeproteinassociationwithagepneumoniadurationoftheperiodaftercovid19 AT svbelenkaya antibodiestothereceptorbindingdomainofthesarscov2spikeproteinassociationwithagepneumoniadurationoftheperiodaftercovid19 AT aaisaeva antibodiestothereceptorbindingdomainofthesarscov2spikeproteinassociationwithagepneumoniadurationoftheperiodaftercovid19 AT dnshcherbakov antibodiestothereceptorbindingdomainofthesarscov2spikeproteinassociationwithagepneumoniadurationoftheperiodaftercovid19 AT saelchaninova antibodiestothereceptorbindingdomainofthesarscov2spikeproteinassociationwithagepneumoniadurationoftheperiodaftercovid19 AT manikonorova antibodiestothereceptorbindingdomainofthesarscov2spikeproteinassociationwithagepneumoniadurationoftheperiodaftercovid19 |